Back to News
Market Impact: 0.12
SIBIONICS ve PharmaSens, EASD 2026'da Otomatik İnsülin Uygulamasında Yeni Ufukları Keşfediyor
Source: PR Newswire
Healthcare & BiotechTechnology & InnovationProduct Launches
SiBionics presented its “See More, Act Earlier” vision at the 2026 European Association for the Study of Diabetes (EASD) Congress in Milan. The company highlighted the integration of continuous glucose-monitoring technology with future diabetes treatment approaches, but the provided article excerpt includes no financial results, clinical data, regulatory decisions, or commercial forecasts.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
More News
- SoftBank’s Masayoshi Son Has Rare Cautionary Note on AI Safety
- Sen. Mitch McConnell closed a loophole in a hemp law he championed. Now a $28 billion THC industry that gets people high is fighting for survival
- Germany's Merz arrives in Kyiv to finalize drone deal, release aid
- Russia hits Kyiv bridge as Germany’s Merz visits Ukraine’s capital
- Germany’s Merz arrives in Kyiv to the sound of sirens and explosions
- Schneider Electric close to $20 bln deal of U.S. software maker PTC - report